Refralon for drug-induced cardioversion of atrial fibrillation in patients with coronary artery disease

Q: What is the clinical evidence from this study?

Study design: Case Report. Population: Atrial fibrillation with coronary artery disease (n=3). Intervention: Refralon (cavutilide). Primary outcome: Successful pharmacological cardioversion.

Q: What does this research mean for the field?

Refralon (cavutilide) can achieve successful pharmacological cardioversion in patients with atrial fibrillation and concomitant structural heart disease. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

M. A. Krymukova; Nikolay Yu. Mironov; Khava M. Dzaurova; Yu. A. Yuricheva; M. M. Belyaeva; V.V. Sviridova; Sergei F. Sokolov; Golitsyn Sp

doi:10.17116/cardiobulletin202419042188

April 22, 2024Russian Cardiology BulletinOpen Access

Refralon for drug-induced cardioversion of atrial fibrillation in patients with coronary artery disease

View Full Paper

Ask AI

Bookmark

Share

Key result

Refralon achieves successful pharmacological cardioversion in 3 patients with AF and structural heart disease.

n=3

Why the study?

Refralon (cavutilide) has not been studied for pharmacological cardioversion of AF in patients with concomitant structural heart diseases including coronary artery disease.

Does Refralon (cavutilide) restore sinus rhythm in patients with atrial fibrillation and concomitant structural heart disease (CAD, prior MI, moderately reduced EF)?

Study Design

Type

Case Report (n=3)

Structured PICO

Does Refralon (cavutilide) restore sinus rhythm in patients with atrial fibrillation and concomitant structural heart disease (CAD, prior MI, moderately reduced EF)?

P

Population

3 patients with atrial fibrillation, coronary artery disease, previous myocardial infarction, and moderately reduced ejection fraction.

I

Intervention

Refralon (cavutilide)

O

Outcome

Successful pharmacological cardioversion (restoration of sinus rhythm)surrogate

Implication

Refralon (cavutilide) may be effective for pharmacological cardioversion of atrial fibrillation in patients with structural heart disease, a population where currently only amiodarone is guideline-approved.

Abstract

Atrial fibrillation (AF) is the leading cause of morbidity and hospitalizations among all cardiac arrhythmias. Moreover, the number of patients with coronary artery disease and other structural heart diseases leading to atrial remodeling increases that predisposes to arrhythmia. Patients with concomitant cardiovascular diseases are more prone to AF-related complications including tachycardia-induced cardiomyopathy. That is why restoration of sinus rhythm is essential in management of these patients. According to clinical guidelines, amiodarone is the only antiarrhythmic drug approved for cardioversion of AF in patients with structural heart diseases. Preliminary results of randomized trial demonstrated superiority of class III drug Refralon (cavutilide) over amiodarone. However, Refralon has not been studied in patients with concomitant structural heart diseases. We analyze 3 successful pharmacological cardioversions by administration of Refralon in patients with atrial fibrillation, coronary artery disease, previous myocardial infarction and moderately reduced ejection fraction.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Krymukova et al. (2024) conducted a case report in Atrial fibrillation with coronary artery disease (n=3). Refralon (cavutilide) was evaluated on Successful pharmacological cardioversion.

synapsesocial.com/papers/6ab5ff58f2584762553cf530 https://doi.org/10.17116/cardiobulletin202419042188